PCDH11Y

Across TCGA pan-cancer cohorts, PCDH11Y mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PCDH11Y data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PCDH11Y mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PCDH11Y expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, GBM, and LSCC are the cancer types where PCDH11Y mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.604	0.161	.001	15	view →
GBM	OS	Median	All	0.654	0.381	.014	12	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.827	.009	8	view →
HNSC	DFS	Quartile	IV	0.583	0.847	.014	7	view →
CCRCC	OS	Median	IV	1.000	0.202	.034	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PCDH11Y–PDAC (DFS)

Open the PDAC breakdown →